Pharmacopsychiatry 2008; 41(6): 259-260
DOI: 10.1055/s-0028-1083822
Letter

© Georg Thieme Verlag KG Stuttgart · New York

No Influence of Dialysis on Mirtazapine – A Case Report

P. M. Schlotterbeck 1 , T. Vehren 1 , S. Milenovic 1 , C. Hiemke 2 , T. Kircher 1 , D. Leube 1
  • 1Department of Psychiatry and Psychotherapy, RWTH, Aachen, Germany
  • 2Department of Psychiatry, University of Mainz, Mainz, Germany
Further Information

Publication History

received 05.05.2008 revised 04.06.2008

accepted 09.06.2008

Publication Date:
09 December 2008 (online)

We examined the concentration of mirtazapine in human plasma during hemodialysis. We detected no significant change in the concentration of this antidepressant before and after the dialysis session. These data provide more security in the treatment of depressive patients who are hemodialysed.

References

  • 1 Klaassen C-D. Principles of toxicology and treatment of poisoning. In: Brunton L, Lazo J, Parker K, eds. Goodman & Gilman's The Pharmacological Basis of Therapeutics. New York: The McGraw-Hill Companies 2005: 1739-1753
  • 2 Murtagh F-E, Addington-Hall J, Higginson I-J. The prevalence of symptoms in end-stage renal disease: a systematic review.  Adv Chronic Kidney Dis. 2007;  14 82-99
  • 3 Shams M, Hiemke C, Härtter S. Therapeutic drug monitoring of the antidepressant mirtazapine and its N-demethylated metabolite in human serum.  Ther Drug Monit. 2004;  26 78-84

Correspondence

P. M.Schlotterbeck 

Im Asemwald 2

70599 Stuttgart

Germany

Phone: +49/711/72 48 38

Email: pschlotterbeck@ukaachen.de